Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science ...

Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability ...

Look into Spain's biotech, an ecosystem that has matured and transforms promissing science into ventures but faces challenges ...

September is often a strong month for the biopharma sector as the industry returns from the summer lull, keen on forging biotech deals.

If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a ...